# A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC

> **NCT06754644** · PHASE3 · RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 808 (estimated)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** QL2107
- **DRUG:** Pemetrexed
- **DRUG:** Carboplatin
- **DRUG:** Keytruda®

## Key facts

- **NCT ID:** NCT06754644
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-15
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 808 (ESTIMATED)
- **Last updated:** 2025-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06754644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06754644, "A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06754644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*